China SXT Valuation
| SXTC Stock | USD 0.38 0.01 2.56% |
China SXT seems to be fairly valued based on Macroaxis valuation methodology. Our model approximates the value of China SXT Pharmaceuticals from analyzing the firm fundamentals such as Profit Margin of (1.61) %, current valuation of (7.87 M), and Return On Equity of -0.22 as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting China SXT's valuation include:
Price Book 0.1117 | Enterprise Value -7.9 M | Enterprise Value Ebitda (0.36) | Price Sales 0.8066 | Enterprise Value Revenue 0.4132 |
Fairly Valued
Today
Please note that China SXT's price fluctuation is out of control at this time. Calculation of the real value of China SXT Pharmaceuticals is based on 3 months time horizon. Increasing China SXT's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since China SXT is currently traded on the exchange, buyers and sellers on that exchange determine the market value of China Stock. However, China SXT's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.38 | Real 0.36 | Hype 0.45 | Naive 0.35 |
The real value of China Stock, also known as its intrinsic value, is the underlying worth of China SXT Pharmaceuticals Company, which is reflected in its stock price. It is based on China SXT's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of China SXT's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of China SXT Pharmaceuticals helps investors to forecast how China stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of China SXT more accurately as focusing exclusively on China SXT's fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use China SXT's intrinsic value based on its ongoing forecasts of China SXT's financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against China SXT's closest peers. If more than one evaluation category is relevant for China SXT we suggest using both methods to arrive at a better estimate.
China SXT Cash |
|
China Valuation Trend
Comparing China SXT's enterprise value against its market capitalization is a good way to estimate the value of China SXT Pharmaceuticals uage its performance over time. This information may sometimes be enough for investors to make reasonable market timing decisions.
China SXT Total Value Analysis
China SXT Pharmaceuticals is at this time anticipated to have valuation of (7.87 M) with market capitalization of 1.56 M, debt of 2.65 M, and cash on hands of 15.52 M. The negative valuation of China SXT may imply that the market is not capable to price the future growth of the company or it is pricing it at zero value. It may also suggest that takeover valuation may not have captured all of the outstanding financial obligations of the company both on and off balance sheet. Investors should vigilantly validate all of the China SXT fundamentals.| Takeover Price | Market Cap | Debt Obligations | Cash |
(7.87 M) | 1.56 M | 2.65 M | 15.52 M |
China SXT Investor Information
About 17.0% of the company outstanding shares are owned by corporate insiders. The company has price-to-book ratio of 0.11. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. China SXT Pharmaceuticals recorded a loss per share of 3.57. The entity had not issued any dividends in recent years. The firm had 1:25 split on the 5th of October 2023. Based on the key indicators related to China SXT's liquidity, profitability, solvency, and operating efficiency, China SXT Pharmaceuticals is not in a good financial situation at this time. It has a very high probability of going through financial hardship in December.China SXT Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. China SXT has an asset utilization ratio of 8.34 percent. This indicates that the Company is making $0.0834 for each dollar of assets. An increasing asset utilization means that China SXT Pharmaceuticals is more efficient with each dollar of assets it utilizes for everyday operations.China SXT Ownership Allocation
China SXT Pharmaceuticals shows 16.94 percent of its outstanding shares held by insiders and 1.34 percent owned by other corporate entities.China SXT Profitability Analysis
The company reported the previous year's revenue of 1.93 M. Net Loss for the year was (3.1 M) with profit before overhead, payroll, taxes, and interest of 1.25 M.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates China SXT's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in China SXT and how it compares across the competition.
About China SXT Valuation
The stock valuation mechanism determines China SXT's current worth on a weekly basis. Our valuation model uses a comparative analysis of China SXT. We calculate exposure to China SXT's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of China SXT's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 554 K | 526.3 K | |
| Pretax Profit Margin | (1.61) | (1.69) | |
| Operating Profit Margin | (1.30) | (1.24) | |
| Net Loss | (1.61) | (1.69) | |
| Gross Profit Margin | 0.29 | 0.48 |
China SXT Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 867.4 K | |
| Quarterly Earnings Growth Y O Y | 0.426 |
China SXT Current Valuation Indicators
Valuation refers to the process of determining the present value of China SXT Pharmaceuticals and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value China we look at many different elements of the entity such as China's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as China SXT, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use China SXT's valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes China SXT's worth.Complementary Tools for China Stock analysis
When running China SXT's price analysis, check to measure China SXT's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy China SXT is operating at the current time. Most of China SXT's value examination focuses on studying past and present price action to predict the probability of China SXT's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move China SXT's price. Additionally, you may evaluate how the addition of China SXT to your portfolios can decrease your overall portfolio volatility.
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing |